언어 선택

TrkC

TrkC 분자 정보

영어 이름	Neurotrophic tyrosine kinase receptor type 3	시판 약물 수	4
임상 약물 수	6	표적 별명	NT-3 growth factor receptor，TrkC tyrosine kinase，Neurotrophic Receptor Tyrosine Kinase 3，Neurotrophic Tyrosine Kinase， Receptor， Type 3，EC:2.7.10.1，GP145-TrkC，TRKC，EC 2.7.10，ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein，Neurotrophic Tyrosine Kinase Receptor Type 3，Tyrosine Kinase Receptor C，ETV6-NTRK3 Fusion，Trk-C，NTRK3，Gp145(TrkC)，EC 2.7.10.1，Receptor， trkC
최고 연구 개발 단계	Approved

영어 이름	Neurotrophic tyrosine kinase receptor type 3
표적 별명	NT-3 growth factor receptor，TrkC tyrosine kinase，Neurotrophic Receptor Tyrosine Kinase 3，Neurotrophic Tyrosine Kinase， Receptor， Type 3，EC:2.7.10.1，GP145-TrkC，TRKC，EC 2.7.10，ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein，Neurotrophic Tyrosine Kinase Receptor Type 3，Tyrosine Kinase Receptor C，ETV6-NTRK3 Fusion，Trk-C，NTRK3，Gp145(TrkC)，EC 2.7.10.1，Receptor， trkC
시판 약물 수	4
임상 약물 수	6
최고 연구 개발 단계	Approved

TrkC 제품 목록

속성
Protein (1)Cell (1)
제품 라이브러리
온라인 (2)
종
Human (2)
태그
Fc Tag (1)Tag Free (1)
마커
Unconjugated (1)- (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
CHEK-ATP189	Human	HEK293	HEK293/Human TrkC Stable Cell Line
TRC-H5256	Human	HEK293	Human TrkC / NTRK3 Protein, Fc Tag (MALS verified)

총 수량2

TrkC분자 배경

Tropomyosin receptor kinase C (TrkC), also known as NT-3 growth factor receptor, neurotrophic tyrosine kinase receptor type 3, or TrkC tyrosine kinase is a protein that in humans is encoded by the NTRK3 gene. It belongs to the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC). TrkC is the high affinity catalytic receptor for the neurotrophin NT-3 (neurotrophin-3). As such, TrkC mediates the multiple effects of this neurotrophic factor, which includes neuronal differentiation and survival.

TrkC분자 별명

NT-3 growth factor receptor,GP145-TrkC,Neurotrophic tyrosine kinase receptor type 3, TrkC tyrosine kinase

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Lestaurtinib	SPM-924; A-154475.0; KT-5555; SP-924; CEP-701	Phase 3 Clinical	Kyowa Hakko Kirin Co Ltd	Bone Marrow Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neuroblastoma; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Psoriasis; Thrombocythemia, Essential	상세
Merestinib	5OGS5K699E; LY-2801653	Phase 2 Clinical	Eli Lilly And Company	Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours	상세
FCN-011	FCN-011	Phase 2 Clinical		Solid tumours	상세
Emzeltrectinib	CT-3417; TQB-3558	Phase 1 Clinical	Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd	Solid tumours	상세
HG-030	HG-030	Phase 1 Clinical	Hitgen Inc	Solid tumours	상세
Paltimatrectinib	PBI-200	Phase 1 Clinical	Pyramid Biosciences	Brain Neoplasms; Desmoplastic Small Round Cell Tumor; Solid tumours	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Taletrectinib Adipate	DS-6051b; DS-6051a; DS-6051; AB-106; IBI-344	Approved	Daiichi Sankyo Co Ltd	达伯乐, DOVBLERON, IBTROZI	Mainland China	Carcinoma, Non-Small-Cell Lung	AnHeart Therapeutics Co Ltd	2024-12-17	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Neoplasms; Solid tumours	상세
Entrectinib	NMS-E628; RXDX-101; RG-6268	Approved	Nerviano Medical Sciences Srl	Rozlytrek, 罗圣全	Japan	Carcinoma, Non-Small-Cell Lung	Chugai Pharmaceutical Co Ltd	2019-06-18	Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Sarcoma; Solid tumours; Thyroid Cancer, Papillary	상세
Larotrectinib sulfate	LOXO-101; ARRY-470; BAY-2757556	Approved	Array Biopharma	Vitrakvi, 维泰凯	United States	Solid tumours	Bayer Healthcare	2018-11-26	Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fibrosarcoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile	상세
Repotrectinib	TPX-0005; BMS-986472; ZL-2308	Approved	Turning Point Therapeutics Inc	Augtyro, 奥凯乐	United States	Carcinoma, Non-Small-Cell Lung	Bristol-Myers Squibb Company	2023-11-15	Brain metastases; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Neoplasms; Solid tumours	상세